On May 31, 2024, the National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), National Center for Advanced Sciences and Technology (NCATS), and Foundation for Advanced Education in the Sciences (FAES) will host the in-person symposium, What about G34R/V Mutated Gliomas?: Challenges and Opportunities.
Register to attend by May 17! Registration is free and space is limited.
G34R/V mutated gliomas are considered a rare disease and are often diagnosed in the young adult/adolescent population. Despite improvements in the diagnostic landscape of these aggressive high grade gliomas, the therapeutic advancements have lagged, leaving clinicians to struggle with optimal treatment options.
During this conference, we will review published and ongoing research centered on G34R/V mutated glioma discoveries to date and discuss via small groups and larger forums on how best to advance research as well as treat these complex patients.
This comprehensive day-long conference is designed for neurooncologists, neurooncology researchers, tumor biologists, oncologists, neurologists, neurosurgeons, neuropathologists, advanced practice nurses, nurses, physician assistants, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with malignant brain tumors.